Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food effect of a standardized Dutch breakfast on alectinib pharmacokinetics using an alectinib-d6 microtracer
NL-OMON56401Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of alectinib in non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Primary endpoints: Food effect on alectinib-d6 pharmacokinetics, Maximum concentration and 2 more. Started Feb 2024; status: completed.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON56401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56401.